633335-94-1

Basic information

• Product Name: Benzene, 4-ethenyl-1-fluoro-2-methoxy- (9CI)
• Synonyms: Benzene, 4-ethenyl-1-fluoro-2-methoxy- (9CI);1-Fluoro-2-methoxy-4-vinylbenzene
• CAS NO: 633335-94-1
• Molecular Formula: C₉H₉FO
• Molecular Weight: 152.1655632
• Product Categories: HALIDE
• Mol File: 633335-94-1.mol

Chemical Properties

• Boiling Point: 207.2±20.0 °C(Predicted)
• Appearance: /
• Density: 1.059±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: Benzene, 4-ethenyl-1-fluoro-2-methoxy- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 4-ethenyl-1-fluoro-2-methoxy- (9CI)(633335-94-1)
• EPA Substance Registry System: Benzene, 4-ethenyl-1-fluoro-2-methoxy- (9CI)(633335-94-1)

Safety Data

• Hazardous Substances Data: 633335-94-1(Hazardous Substances Data)

Upstream product

• 128495-46-5 4-fluoro-3-methoxybenzaldehyde 
• 19493-09-5 Methylenetriphenylphosphorane 
• 1779-49-3 Methyltriphenylphosphonium bromide 

Downstream Products

• 1421503-46-9 2-(2-ethyl-5-fluoro-4-methoxy-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane 
• 1421503-51-6 3-(trimethylstannyl)-6-(2-ethyl-5-fluoro-4-methoxyphenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole 
• 1234845-77-2 4-ethyl-1-fluoro-2-methoxy-benzene 
• 1421503-45-8 1-bromo-2-ethyl-5-fluoro-4-methoxy-benzene 
• 1421503-47-0 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-indazole 
• 1421503-48-1 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1H-indazole 
• 1421503-49-2 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-3-iodo-1H-indazole 
• 1421503-50-5 6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-3-iodo-1-(tetrahydro-pyran-2-yl)-1H-indazole 
• 1421503-55-0 2-[6-(2-ethyl-5-fluoro-4-methoxy-phenyl)-1-(tetrahydro-pyran-2-yl)-1H-indazol-3-yl]-1-(2-trimethylsilanyl-ethoxymethyl)-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester 

Relevant articles and documents

Visible Light-Promoted Three-Component Carboazidation of Unactivated Alkenes with TMSN3 and Acrylonitrile

A novel difunctionalization of unactivated alkenes has been reported via visible light-promoted three-component carboazidation using TMSN3 and acrylonitrile as partners without any stoichiometric oxidants. This protocol is operationally simple for straightforward access to azido derivatives with good functional group tolerance from readily available starting materials. A facile azido radical-catalyzed [3?+?2] cycloaddition reaction of vinylcyclopropane with acrylonitrile was also observed to deliver a multi-substituted cyclopentane.

FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND

The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.

GPR120 RECEPTOR AGONISTS AND USES THEREOF

GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

GPR120 RECEPTOR AGONISTS AND USES THEREOF

GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

GPR120 RECEPTOR AGONISTS AND USES THEREOF

GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

2-(1-OXO-1H-ISOQUINOLIN-2-YL)ACETAMIDE DERIVATIVES

Disclosed herein are 2-(1-oxo-1H-isoquinolin-2-yl)acetamide derivative of formula I, or pharmaceutically acceptable salts or solvates thereof wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions comprising 2-(1-oxo-1H-isoquinolin-2-yl)acetamide derivatives according to the present invention and their use in therapy.